Anebulo Pharmaceuticals, Inc.
ANEB
$2.30
-$0.01-0.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.92M | 4.59M | 4.25M | 4.58M | 4.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.22M | 8.23M | 8.01M | 8.18M | 8.31M |
| Operating Income | -9.22M | -8.23M | -8.01M | -8.18M | -8.31M |
| Income Before Tax | -8.48M | -7.69M | -7.67M | -7.92M | -8.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.48 | -7.69 | -7.67 | -7.92 | -8.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.48M | -7.69M | -7.67M | -7.92M | -8.20M |
| EBIT | -9.22M | -8.23M | -8.01M | -8.18M | -8.31M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.27 | -0.27 | -0.29 | -0.31 | -0.32 |
| Normalized Basic EPS | -0.17 | -0.17 | -0.18 | -0.19 | -0.20 |
| EPS Diluted | -0.27 | -0.27 | -0.29 | -0.31 | -0.32 |
| Normalized Diluted EPS | -0.17 | -0.17 | -0.18 | -0.19 | -0.20 |
| Average Basic Shares Outstanding | 135.52M | 120.37M | 105.22M | 103.59M | 103.29M |
| Average Diluted Shares Outstanding | 135.52M | 120.37M | 105.22M | 103.59M | 103.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |